Glucose Metabolism and Sex Hormones in Male Patients with Medication-naïve First-episode Schizophrenia: A Large-scale Cross-sectional Study
- PMID: 38549523
- PMCID: PMC11337684
- DOI: 10.2174/1570159X22666240212141602
Glucose Metabolism and Sex Hormones in Male Patients with Medication-naïve First-episode Schizophrenia: A Large-scale Cross-sectional Study
Abstract
Background: Schizophrenia (SCZ) usually begins in early adult life. The underlying molecular mechanisms of SCZ remain unclear. There is evidence for the involvement of abnormalities in metabolic and endocrine systems in SCZ, even in drug-naïve first-episode schizophrenia patients (DNFES). However, the association between impaired regulation of glucose metabolism and sex hormones was not studied in SCZ. This study aimed to evaluate the interrelationship between sex hormones and high fasting glucose levels in male DNFES patients.
Methods: A total of 99 patients with SCZ were recruited, and fasting glucose, fasting insulin, the insulin resistance index (HOMA-IR), and sex hormones were measured.
Results: We found that some male patients with SCZ had abnormal levels in glucose metabolism parameters and gonadal hormones that were not within the normal range. Linear regression analysis adjusted for age, waist circumference, and body mass index showed that testosterone levels were negatively associated with fasting insulin in male patients (β = -0.21, t = -2.2, p = 0.03).
Conclusion: Our findings confirm the abnormalities in glucose metabolism parameters and gonadal hormones at the onset of the illness in male DNFES patients with SCZ. In addition, there was an interaction effect between abnormal glucose metabolism and sex hormones in male patients.
Keywords: Schizophrenia; fasting insulin; first-episode; glucose metabolism; male patients.; sex hormones.
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
Conflict of interest statement
The authors declare no conflict of interest, financial or otherwise.
References
-
- Nguyen K.D., Amerio A., Aguglia A., Magnani L., Parise A., Conio B., Serafini G., Amore M., Costanza A. Microglia and other cellular mediators of immunological dysfunction in schizophrenia: A narrative synthesis of clinical findings. Cells. 2023;12(16):2099. doi: 10.3390/cells12162099. - DOI - PMC - PubMed
-
- Mitchell A.J., Vancampfort D., Sweers K., van Winkel R., Yu W., De Hert M. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders: A systematic review and meta-analysis. Schizophr. Bull. 2013;39(2):306–318. doi: 10.1093/schbul/sbr148. - DOI - PMC - PubMed
-
- Correll C.U., Solmi M., Veronese N., Bortolato B., Rosson S., Santonastaso P., Thapa-Chhetri N., Fornaro M., Gallicchio D., Collantoni E., Pigato G., Favaro A., Monaco F., Kohler C., Vancampfort D., Ward P.B., Gaughran F., Carvalho A.F., Stubbs B. Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: A large‐scale meta‐analysis of 3,211,768 patients and 113,383,368 controls. World Psychiatry. 2017;16(2):163–180. doi: 10.1002/wps.20420. - DOI - PMC - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
